We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-5.98%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$106M
AUM Growth
-$10.8M
Cap. Flow
+$478K
Cap. Flow %
0.45%
Top 10 Hldgs %
66.88%
Holding
54
New
8
Increased
10
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
ARCT icon
Arcturus Therapeutics
ARCT
+$1.3M
2
RIOT icon
Riot Platforms
RIOT
+$1.25M
3
ECI
ENCISION INC
ECI
+$1.13M
4
OCRX
Ocera Therapeutics, Inc.
OCRX
+$776K
5
FATE icon
Fate Therapeutics
FATE
+$535K

Top Sells

Rank Stock Value
1
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$2.6M
2
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$1.53M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$873K
4
DMK
DMK Pharmaceuticals Corporation Common Stock
DMK
+$795K
5
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
+$691K

Sector Composition

Rank Sector Weight
1 Healthcare 82.37%
2 Miscellaneous 16.24%
3 Financials 1.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMPE
1
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$11.7M 11.09%
4,670
-749
-14% -$1.53M
ATRC icon
2
AtriCure
ATRC
$2.47B
$10.5M 9.95%
570,987
– –
PCYC
3
DELISTED
PHARMACYCLICS INC
PCYC
$10.4M 9.83%
115,628
+5,000
+5% +$469K
WINT
4
DELISTED
Windtree Therapeutics Inc
WINT
$10.1M 9.61%
407,053
– –
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
$5.52M 5.23%
384,154
– –
STXS icon
6
Stereotaxis
STXS
$145M
$4.9M 4.65%
1,726,825
– –
DSCI
7
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$4.45M 4.22%
384,794
– –
NVDQ
8
DELISTED
Novadaq Technologies Inc.
NVDQ
$4.34M 4.12%
263,541
– –
PODD icon
9
Insulet
PODD
$10.1B
$4.34M 4.11%
109,418
– –
PLX icon
10
Protalix BioTherapeutics
PLX
$205M
$4.3M 4.08%
117,844
– –
VXRT
11
DELISTED
Vaxart
VXRT
$2.08M 1.97%
66,344
– –
GLMD icon
12
Galmed Pharmaceuticals
GLMD
$4.34M
$2.01M 1.9%
143
+3
+2% +$36.9K
BSTC
13
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.89M 1.79%
70,088
– –
CRDC
14
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.69M 1.61%
148,600
+43,230
+41% +$439K
BEAT
15
DELISTED
BioTelemetry, Inc.
BEAT
$1.69M 1.6%
235,645
+20,000
+9% +$159K
MTEM
16
DELISTED
Molecular Templates, Inc.
MTEM
$1.56M 1.47%
2,382
+743
+45% +$492K
ARCT icon
17
Arcturus Therapeutics
ARCT
$432M
$1.47M 1.39%
12,142
+10,768
+784% +$1.3M
RIOT icon
18
Riot Platforms
RIOT
$7.13B
$1.47M 1.39%
82,250
+73,125
+801% +$1.25M
KERX
19
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.42M 1.35%
92,400
-7,600
-8% -$108K
OCRX
20
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.23M 1.16%
160,622
+97,399
+154% +$776K
UPI
21
DELISTED
UROPLASTY INC-NEW
UPI
$1.18M 1.12%
441,859
+152,527
+53% +$479K
XNPT
22
DELISTED
XENOPORT, INC.
XNPT
$1.16M 1.1%
240,190
+20,000
+9% +$84.8K
ECI
23
DELISTED
ENCISION INC
ECI
$1.13M 1.07%
+1,062,500
New +$1.13M
JNJ icon
24
Johnson & Johnson
JNJ
$646B
$983K 0.93%
9,400
– –
SPNC
25
DELISTED
Spectranetics Corp
SPNC
$965K 0.91%
42,162
– –
1
2 3

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, DAFNA Capital Management held 54 positions worth $106M, down 9.3% from $116M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

DAFNA Capital Management's Q2 2014 filing shows 8 new, 10 increased, 2 reduced and 5 closed positions. Its largest new stake was ENCISION INC: 1,062,500 shares worth $1.13M. The largest sale was Merrimack Pharmaceuticals, Inc., an estimated $2.6M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier, followed by Miscellaneous and Financials.

  • DAFNA Capital Management's largest Q2 2014 buy was ENCISION INC: 1,062,500 shares worth $1.13M.
  • DAFNA Capital Management added most to Arcturus Therapeutics in Q2 2014, an estimated $1.3M increase.
  • DAFNA Capital Management's biggest Q2 2014 reduction was Ampio Pharmaceuticals Inc., cutting an estimated $1.53M.
  • DAFNA Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2014, selling an estimated $2.6M.
  • DAFNA Capital Management's ten largest holdings make up 67% of its $106M portfolio in Q2 2014.
  • DAFNA Capital Management opened 8 new positions and closed 5 in Q2 2014.
  • DAFNA Capital Management's portfolio value fell 9.3% quarter-over-quarter to $106M.

Based on DAFNA Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.